Philip Mease, MD

Medical Center/Providence St. Joseph Health and University of Washington, Seattle

Dr. Mease received his undergraduate and medical degrees from Stanford University, completedresidency in internal medicine and fellowship in rheumatology at the University of Washington He caresfor patients at Seattle Rheumatology Associates and directs the rheumatology research division atSwedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at theUniversity of Washington in Seattle.Dr. Mease’s research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA), rheumatoidarthritis (RA), osteoarthritis (OA), fibromyalgia (FM) and osteoporosis. His research focuses on diseasestate, outcome measure development, and determining the efficacy and safety of emerging therapiesfor these conditions. His seminal 2000 Lancet paper established the efficacy of anti-TNF therapy in PsA.He has authored over 500 journal articles, many hundreds of abstracts, book chapters and editedtexbooks on PsA and AxSpA. He is a prolific international speaker at academic congresses, grand roundsand other educational activities for rheumatologists and dermatologists and is considered aninternational key opinion leader, researcher, educator and clinician regarding spondyloarthritis,including psoriatic arthritis, ankylosing spondylitis and non-radographic spondyloarthritis. He is areviewer for multiple journals including New England Journal of Medicine, Lancet, Arthritis &Rheumatology, Arthritis Care & Research, Annals of the Rheumatic Diseases, The Journal ofRheumatology, and Seminars in Arthritis and Rheumatism.Dr. Mease is past president and founding organizer of the Group for Research and Assessment ofPsoriasis and Psoriatic Arthritis (GRAPPA), an international organization of over 800 rheumatology anddermatology researchers dedicated to research and education about psoriasis and psoriatic arthritis. Heis a member of the Assessment of Spondyloarthritis international Society (ASAS) and theSpondyloarthritis Research and Treatment Network (SPARTAN). Dr Mease has been active in theOutcome Measures in Rheumatology Clinical Trials (OMERACT) research organization as co-chair of thePsA and chronic pain working groups and serving on the steering committee. He is an active mentor ofyoung investigators in these organizations. He serves in an educational and advisory role for the FDA.He serves on the steering committee of the arthritis section of the International Consortium for HealthOutcomes Measurement (ICHOM). He conducts disease state research in registries such as theConsortium of Rheumatology Researchers of North America (CORRONA) for which he is Director of theSpondyloarthritis and Psoriatic Arthritis arm of the registry, now tracking over 4000 subjects in the US.He is a member of The Rheumatology Education Group (TREG). Dr Mease is a Master of the AmericanCollege of Rheumatology (ACR) and has received its Medical Communicator of the Year Award for histeaching at the ACR and in the community. He is a co-chair of the ACR abstract review committeesection on Spondyloarthritis and Psoriatic Arthritis. He serves on the Voting Committee for the ACR-NPF(National Psoriasis Foundation) Psoriatic Arthritis treatment guidelines task force. He is co-chair of thePsA task force of the NPF which in 2019 awarded Dr. Mease a lifetime achievement award for his workin advancing the field of PsA. He is past President of the Northwest Rheumatism Society.

Sessions Associated

©2022 SPARTAN-AM21. All Rights Reserved. Powered by Performedia

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram